
|Articles|August 1, 2007
- Volume 0 0
ADVISORY COMMITTEE WILL ADDRESS RISK COMMUNICATION
Advertisement
The FDA will form a new advisory committee of outside specialists to advise the agency on how to inform the public about the risks and benefits of medicines and medical devices. The Risk Communication Advisory Committee will:
- Help the FDA better understand the communication needs and priorities of the general public
- Advise the FDA on the development of strategic plans to communicate product risks and benefits
- Make recommendations to the FDA based on current research about crafting risk and benefit messages, as well as how to effectively communicate specific product information to vulnerable audiences
The committee "will bring together a broad range of experts and views to help improve the FDA's communication of the science-based information about product risks and benefits that the public needs to make informed decisions."
Articles in this issue
about 19 years ago
The Facts of Liceabout 19 years ago
compounding HOTLINEabout 19 years ago
can you READ these Rxs?about 19 years ago
can you READ these Rxs?about 19 years ago
WARFARIN-RELATED COMPLICATIONS INCREASE WITH AGEabout 19 years ago
IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?about 19 years ago
HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMESabout 19 years ago
LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERSabout 19 years ago
Embracing and Advocating Change in the Pharmacy Professionabout 19 years ago
Improving Pharmaceutical Care of the Elderly Patient with GERDAdvertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Testing categories in practice — clinical conversations
2
FDA Grants Accelerated Approval to Iberdomide Combination for Multiple Myeloma
3
COVID-19 Variant Surveillance: A Primer for Pharmacists Navigating Vaccine Questions
4
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
5






































































































